Want to see VIR full AI Analyst Report?

Vir Biotechnology (VIR) Stock Forecast & Price Target

1,554 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

VIR Analyst Ratings

Strong Buy

8 Buy

0 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Vir

Biotechnology

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

VIR Stock 12 Month Forecast

Average Price Target

$21.29

▲(144.94% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Vir Biotechnology in the last 3 months. The average price target is $21.29 with a high forecast of $30.00 and a low forecast of $15.00. The average price target represents a 144.94% change from the last price of $8.69.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","31":"$31","10.75":"$10.75","17.5":"$17.5","24.25":"$24.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.285714285714285,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$21.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$15.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,10.75,17.5,24.25,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.66,10.301538461538462,11.943076923076923,13.584615384615386,15.226153846153846,16.86769230769231,18.50923076923077,20.15076923076923,21.792307692307695,23.433846153846154,25.075384615384618,26.716923076923077,28.35846153846154,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.66,9.631208791208792,10.602417582417582,11.573626373626373,12.544835164835165,13.516043956043955,14.487252747252747,15.458461538461538,16.42967032967033,17.400879120879118,18.372087912087913,19.3432967032967,20.314505494505493,{"y":21.285714285714285,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.66,9.147692307692308,9.635384615384616,10.123076923076923,10.61076923076923,11.098461538461539,11.586153846153847,12.073846153846155,12.561538461538461,13.04923076923077,13.536923076923078,14.024615384615384,14.512307692307694,{"y":15,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.03,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.7,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.96,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.07,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.03,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.71,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.34,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.02,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.03,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.56,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.66,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$30.00

Average Price Target$21.29

Lowest Price Target$15.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Patrick Trucchio

H.C. Wainwright

$20

Buy

130.15%

Upside

Reiterated

08/10/26

Analyst Reiterates Buy on Vir Biotechnology, Maintains $20 Price Target Amid Strong Late-Stage HDV Momentum and Solid Cash Runway

Alec Stranahan

Bank of America Securities

$16→$15

Buy

72.61%

Upside

Reiterated

08/07/26

Vir Biotechnology (VIR) Receives a Buy from Bank of America Securities

Etzer Darout

Barclays

$30

Buy

245.22%

Upside

Reiterated

08/06/26

Vir Biotechnology (VIR) Gets a Buy from Barclays

Cory Kasimov

Evercore ISI

$22

Buy

153.16%

Upside

Reiterated

08/06/26

Evercore ISI Sticks to Its Buy Rating for Vir Biotechnology (VIR)

Joseph Stringer

Needham

$18

Buy

107.13%

Upside

Reiterated

08/06/26

Vir Biotechnology: Buy Rating Reaffirmed on De-Risking HDV Franchise and Market-Building Tailwinds; $18 Price Target Unchanged

Michael Ulz

Morgan Stanley

$27→$25

Buy

187.69%

Upside

Assigned

08/06/26

Morgan Stanley Keeps Their Buy Rating on Vir Biotechnology (VIR)

Roanna Ruiz

Leerink Partners

$21→$19

Buy

118.64%

Upside

Reiterated

08/06/26

Vir Biotechnology price target lowered to $19 from $21 at LeerinkVir Biotechnology price target lowered to $19 from $21 at Leerink

Phil Nadeau

TD Cowen

―

Buy

―

Reiterated

08/05/26

Analyst Reiterates Buy on Vir Biotechnology, Citing Advancing Hepatitis D and Oncology Pipelines and Strong Cash Runway

Paul Choi

Goldman Sachs

$21

Buy

141.66%

Upside

Reiterated

05/06/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Revolution Medicines (NASDAQ: RVMD), LivaNova (NASDAQ: LIVN) and Vir Biotechnology (NASDAQ: VIR)

Sean McCutcheon

Raymond James

$12→$19

Buy

118.64%

Upside

Reiterated

02/24/26

Vir Biotechnology upgraded to Strong Buy from Outperform at Raymond JamesVir Biotechnology upgraded to Strong Buy from Outperform at Raymond James

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Patrick Trucchio

H.C. Wainwright

$20

Buy

130.15%

Upside

Reiterated

08/10/26

Analyst Reiterates Buy on Vir Biotechnology, Maintains $20 Price Target Amid Strong Late-Stage HDV Momentum and Solid Cash Runway

Alec Stranahan

Bank of America Securities

$16→$15

Buy

72.61%

Upside

Reiterated

08/07/26

Vir Biotechnology (VIR) Receives a Buy from Bank of America Securities

Etzer Darout

Barclays

$30

Buy

245.22%

Upside

Reiterated

08/06/26

Vir Biotechnology (VIR) Gets a Buy from Barclays

Cory Kasimov

Evercore ISI

$22

Buy

153.16%

Upside

Reiterated

08/06/26

Evercore ISI Sticks to Its Buy Rating for Vir Biotechnology (VIR)

Joseph Stringer

Needham

$18

Buy

107.13%

Upside

Reiterated

08/06/26

Vir Biotechnology: Buy Rating Reaffirmed on De-Risking HDV Franchise and Market-Building Tailwinds; $18 Price Target Unchanged

Michael Ulz

Morgan Stanley

$27→$25

Buy

187.69%

Upside

Assigned

08/06/26

Morgan Stanley Keeps Their Buy Rating on Vir Biotechnology (VIR)

Roanna Ruiz

Leerink Partners

$21→$19

Buy

118.64%

Upside

Reiterated

08/06/26

Vir Biotechnology price target lowered to $19 from $21 at LeerinkVir Biotechnology price target lowered to $19 from $21 at Leerink

Phil Nadeau

TD Cowen

―

Buy

―

Reiterated

08/05/26

Analyst Reiterates Buy on Vir Biotechnology, Citing Advancing Hepatitis D and Oncology Pipelines and Strong Cash Runway

Paul Choi

Goldman Sachs

$21

Buy

141.66%

Upside

Reiterated

05/06/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Revolution Medicines (NASDAQ: RVMD), LivaNova (NASDAQ: LIVN) and Vir Biotechnology (NASDAQ: VIR)

Sean McCutcheon

Raymond James

$12→$19

Buy

118.64%

Upside

Reiterated

02/24/26

Vir Biotechnology upgraded to Strong Buy from Outperform at Raymond JamesVir Biotechnology upgraded to Strong Buy from Outperform at Raymond James

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

AMLXAmylyx Pharmaceuticals Inc

IMMXImmix Biopharma

JBIOJade Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Vir Biotechnology

3 Months

Phil NadeauTD Cowen

Success Rate

10/18 ratings generated profit

Average Return

+7.72%

Copying Phil Nadeau's trades and holding each position for 3 Months would result in 55.56% of your transactions generating a profit, with an average return of +7.72% per trade.

1 Year

Patrick TrucchioH.C. Wainwright

Success Rate

11/17 ratings generated profit

Average Return

+12.96%

Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 64.71% of your transactions generating a profit, with an average return of +12.96% per trade.

2 Years

Patrick TrucchioH.C. Wainwright

Success Rate

12/17 ratings generated profit

Average Return

+24.56%

Copying Patrick Trucchio's trades and holding each position for 2 Years would result in 70.59% of your transactions generating a profit, with an average return of +24.56% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VIR Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, VIR has received 11 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. VIR average Analyst price target in the past 3 months is 21.29.

Each month's total comprises the sum of three months' worth of ratings.

VIR Financial Forecast

VIR Earnings Forecast

Next quarter’s earnings estimate for VIR is -$0.73 with a range of -$0.95 to -$0.58. The previous quarter’s EPS was $0.47. VIR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year VIR has Performed in-line its overall industry.

VIR Sales Forecast

Next quarter’s sales forecast for VIR is $865.00K with a range of $0.00 to $2.80M. The previous quarter’s sales results were $238.95M. VIR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year VIR has Performed in-line its overall industry.

VIR Stock Forecast FAQ

What is VIR’s average 12-month price target, according to analysts?

Based on analyst ratings, Vir Biotechnology, Inc.’s 12-month average price target is 21.29.

What is VIR’s upside potential, based on the analysts’ average price target?

Vir Biotechnology, Inc. has 144.94% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is VIR a Buy, Sell or Hold?

Vir Biotechnology, Inc. has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.

What is Vir Biotechnology, Inc.’s price target?

The average price target for Vir Biotechnology, Inc. is 21.29. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $30.00 ,the lowest forecast is $15.00. The average price target represents 144.94% Increase from the current price of $8.69.

What do analysts say about Vir Biotechnology, Inc.?

Vir Biotechnology, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of VIR?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Vir Biotechnology (VIR) Stock Forecast & Price Target

VIR Analyst Ratings

VIR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Vir Biotechnology

VIR Analyst Recommendation Trends

VIR Financial Forecast

VIR Earnings Forecast

VIR Sales Forecast

VIR Stock Forecast FAQ

Detailed List of Analyst Forecasts